Research Articles and Patents
INDEX
Papers relative to the Microbe Electrifier:
Biocompatible Electric Current Attenuates HIV-1
Infectivity
PATENT 5,139,684; Electrically conductive
methods and systems for treatment of blood
Papers relative to the DC Electrifier:
Medical Hypothesis; A Novel Therapy For Cancer
Electro-Carcinoma Therapy
Electric
Current Helps Wipe Out Liver Tumours
Antioxidant
Effects of Ultra-Low Microcurrents
Electric Current
Helps Diabetic Foot Ulcers Heal
Papers relative to the Beck
Pulser:
Quotes from Various Patents about Pulsed
Electro-Magnetic Fields (PEMF)
Health Effects of
Electro-Magnetic Fields
Papers relative to the OMF
Generator:
Patent 4,665,898: Malignancy Treatment
Patent 4,524,079; Deactivation of Microorganisms by an Oscillating
Magnetic Field
Kinetics of Microbial Inactivation for
Alternative Food Processing Technologies Oscillating Magnetic
Fields
Papers relative to the Candida
Zapper:
STUDIES ON THE EFFECT OF MEDIKZAP AND NE 555 DEVICES
USED IN NATURAL MEDICINE ON THE CANDIDA ALBICANS
FUNGUS
Papers relative to the Diabetes
Zapper:
Ultra-low microcurrent in the management of diabetes
mellitus, hypertension and chronic wounds: Report of twelve cases and discussion
of mechanism of action
Papers relative to the Herpes
Zapper:
Patent 5,133,352: Method for Treating Herpes
Simplex
Health Effects of Electro-Magnetic Fields
from Science News, Vol. 156, No. 20
November 13, 1999,
p.
316
http://www.sciencenews.org/sn_arc99/11_13_99/bob2.htm
http://www.sciencenews.org/sn_arc99/11_13_99/bob2ref.htm
Two previous studies had found that
electro-magnetic fields (EMFs) reduce pain and swelling. EMFs also have that
effect in a new trial headed by orthopedic surgeon Roy K. Aaron. Presumably, he
says, it does it "by changing the chemistry of the joint." Studies by his team
and others indicate that these fields can increase a joint's production of
natural anti-inflammatory agents, such as transforming growth factor-beta. Not
surprisingly, Aaron notes, medical supply companies are now developing products,
such as a glove with coils, to deliver EMFs to arthritis-ravaged joints. Softer
tissues also respond to these fields. For instance, Arthur A. Pilla, a
biophysicist at the Mount Sinai School of Medicine in New York City, observes
that many people with bone breaks experience significant pain in muscles around
their injuries. Shortly after EMF therapy begins, however, that pain disappears.
Though the mechanism remains elusive, Pilla says, the treatment seems to affect
swelling, which can cause pain. If this proves true, he says, EMFs might benefit
people with carpal tunnel syndrome, where swelling in the wrist pinches nerves
going to the fingers. Indeed, that's a possibility that Betty F. Sisken of the
University of Kentucky College of Medicine in Lexington would like to explore.
Currently, she's probing EMFs' direct influence on nerves. In their initial
studies, she and her colleagues crushed a nerve in the hind leg of rats and then
treated the animals with EMFs for 4 hours daily.
BIOCOMPATIBLE ELECTRIC CURRENT ATTENUATES HIV-1
INFECTIVITY
William D. Lyman, Irwin R.
Merkatz
William C. Hatch and Steven C. Kaali
Departments of Pathology, and
Obstetrics & Gyneclogy
Albert Einstein College of Medicine,
1300
Morris Park Ave. Bronx, N.Y.
10461
Summary
In this report, we
present the results of double-blinded studies on the use of direct electric
current to alter the infectivity of HIV-1 for susceptible cells in vitro. These
experimental currents were equal to 3.85 and 7.7µA/mm2 current
densities respectively. The reduction of infectivity was dependent upon the
total electric charge (µA x min) passing through the chamber to which the virus
was exposed. Viral infectivity was determined by two independent measures: a
syncytium-formation assay which can be used to quantify the production of
infectious particles; and a reverse transcriptase assay which is an index of
viral protein production.
Results
Syncytium-formation
assay:
Using this index of HIV-1 infectivity, it was determined
that exposing virus to direct electric current suppressed its capacity to induce
the formation of syncytia. Figure 1 shows a representative experiment and Table
2 shows the Croup data for 3 separate experiments. As can be noted in Figure 1,
a statistically significant (p<0.001) reduction in syncytium number was
absented and this reduction was dependent upon the current applied to the viral
isolate. At three different viral dilutions, there were analogous results in
that a total charge of 200µA x min (25µA for 8 minutes) reduced the number of
syncytia from 50% to 65% while a charge of 3O0µA x min (50µA for 6 minutes, 75µA
for 4 minutes or 100µA for 3 minutes) resulted in 90%
reduction.
Reverse transcriptase assay:
The direct
electric currents to which HIV-l was exposed also reduced reverse transcriptase
activity. Five separate experiments were conducted and a representative
experiment is shown in Figure 2 and the data are included in Table 3. As can be
seen in Figure 2, there was a significant decrease in the amount of reverse
transcriptase activity after exposure of the virus to either 50A for 3 or 6
minutes. An equivalent reduction in reverse transcriptase activity was also
noted with exposure to 100µA for 3 minutes and almost ablation of reverse
transcriptase activity was seen with exposure of the viral isolate to 100µA for
6 minutes. The group data (Table 3) show that after exposure to 50µA for 6
minutes, there was a 44% reduction in activity and treatment of virus with 100µA
for 6 minutes resulted in a 94% reduction. An analysis of variance indicates
that the decrease in reverse transcriptase activity was statistically
significant (p<0.0001).
DISCUSSION
The results
reported here demonstrate that HIV-1 treated with direct electric currents from
50 to 100µA has a significantly reduced infectivity for susceptible cells in
vitro. This reduction of infectivity correlates with the total electric charge
passing through the chamber. The therapeutic potential of electric current may
reside in its ability to lower the viral titer to subclinical significance or in
its incorporation into a strategy analogous to that of other therapies in which
repeated cycles of treatment eventually achieve remission or cure. It may be
also feasible to treat AIDS patients with direct electric current using either
extracorporeal [out of body] systems or self contained indwelling electrodes.
Figure l
Syncytium Formation at 1:160
dilution
exposure (µA/minute) 0/6 25/8 50/6 75/4 100/3
# of syncytium formed 128 45 9 7 2
Five aliquots of
the RF strain of HIV-1 were exposed to direct electric current. At all the
dilutions tested, electrical treatment of the virus aliquots resulted in a
significant decrease in syncytium formation.
Figure 2
Reverse
Transcriptase Activity exposure (µA/minute) 0/3 0/6 50/3 50/6 100/3 100/6
reverse transcriptase 300 205 108 105 100 12 count per million x 10-3
Six aliquots of the RF strain of HIV-1 were exposed to
different amounts of current for 3 or 6 minutes. A significant decrease
(p<0.005) from 0 current levels (0/3 and 0/6) in reverse transcriptase
activity is noted. However, the decrease is more significant (p<0.0001) when
virus is exposed to 100µA for 6 minutes.
Michael's
Notes:
Human CD4 immune blood cells were exposed to various amounts of
electric current for various amounts of time and then mixed with HIV-1 virus.
The resultant decrease in CD4 infection by the virus (resulting in cell
enlargement [syncytium] and reverse transcriptase production) is listed in the
two tables under the column headings indicating how much electric current in
microamperes (µA= millionths of an ampere) was applied to the virus for how many
minutes. 100µA applied for 3 minutes to the virus produced only approximately 2%
of the number of enlarged cells (syncytium) as was produced after 6 minutes
without electrical treatment of the virus. 100µA is equal to 7.7µA per square
millimeter (mm2) of the surface of the electrodes delivering the
electric current to the virus. Explanation of tests: Human CD4 immune cells,
when exposed to HIV-1 virus, normally become infected with the virus and then
enlarged as the virus reproduces itself (with the coerced help of the blood
cell) within the CD4 cell. So anything that can reduce the viral infectivity
(the ability of the virus to infect a cell) can be tested in the laboratory to
see if less enlarged cells (syncytium) are produced which will show the degree
of success of the anti-viral. Reverse transcriptase is an enzyme used by
retroviruses to form a complementary DNA sequence (cDNA) from their RNA. The
resulting DNA is then inserted into the chromosome of the host cell. A test
showing how much is being produced is a way to quantify approximately how much
viral reproduction has happened as a result of viral infection of the CD4 cells.
So a test result showing reduced reverse transcriptase activity is one that
shows how successful an anti-viral is at reducing the infectivity of a
virus.
U.S. PATENT 5,139,684
By Steven Kaali and Peter
Schwolsky
Filed 11-16-1990, approved 8-18-1992
Electrically conductive
methods and systems for treatment of blood and other body fluids and/or
synthetic fluids with electric forces
Claimed:
"...applying... no biologically damaging electric
potentials... to the electrically conductive electrode segments whereby electric
field forces are produced... that induce biologically compatible current flow
through the blood... to attenuate bacteria, virus, parasites, fungus contained
in the blood... to render the bacteria, virus, parasites, fungus ineffective
while not impairing the biological usefulness of the
fluids"
Summary:
"...to attenuate such contaminants
to the extent that bacteria, virus, or fungus, or parasites contained in the
blood... are rendered ineffective to infect or affect healthy
cells."
Best Mode of Practicing Invention:
"For
example, treatment of AIDS virus in media at 100 microamperes for 3 minutes has
been observed to substantially attenuate (render ineffective) the AIDS
virus."
Experimental Results:
"In conclusion, these
experiments... indicate at a statistically significant level that direct
electric current... can attenuate the ability of HIV-1 to infect normally
healthy cells which are susceptible to the HIV-1 AIDS virus." "Both of these
assays (syncytia & reverse transcriptase) are widely used as reproducible
measures of viral infection and can be used to determine if alternations in
viral infectivity as a product of this electrical treatment can be detected."
"...it is believed obvious that other modifications and variations of the
invention will be suggested to those skilled in the art in the light of the
above teachings." "...it is possible that certain virus may be attenuated (or
attenuated at a faster rate) if they are exposed to a greater electric current
magnitude of the order of 500 microamperes for shorter time
periods."
Michael's Notes:
The patent's 1st
laboratory test used electrically treated (at 100µA/3min which is 7.7µA per
square millimeter for 3 minutes) HIV-l virus mixed with human T cells (immune
cells which the HIV likes to infect) and showed 99% less infected & enlarged
T cells (syncytia) by viruses after 4 days compared to T cells mixed with HIV-1
not electrically treated. The patents 2nd lab test used electrically treated
(l00µA/6min) HIV-1 mixed with blood T cells and showed 72% less virus associated
enzymes (reverse transcriptase produced as a result of viral reproduction) after
4 days, compared to T cells mixed with HIV-1 not treated. So to equate
7.7µA/sqmm (the most important parameter) through blood in your arms brachial
artery* (that runs from elbow to elbow) that has an average cross sectional area
of 16 square mm you need to multiply 16 by 7.7 to get .124mA, whereas 50µA
equates to .062mA from a blood electrifier. But the electricity winds up in both
arteries crossing the body between the shoulders and so this amount needs to be
doubled in order to maintain the same current density. 2x.062=.124 and
2x.124=.248. Using the electrodes wrist to wrist does not necessitate applying
more than .25mA for optimal effectiveness. Due to the short durations of
exposure to the electricity, as the blood passes through the main arteries (~ 1
minute), it is necessary to do treatments of up to 1 - 2 hours. [see more of this
patent]
U.S.
Patent 4,665,898
Inventor: Jonathan L. Costa, Gunter A. Hofmann
Date:
May 19, 1987
Malignancy
Treatment
Abstract
A body part of an animal
afflicted with malignant cells is disposed within a magnetic coil and subjected
to a plurality of magnetic field pulses, the pulses having intensities of
between about l and about 100 Tesla and characteristic frequencies of between
about 5 and about 100 kHz. The pulses magnetic field selectively inactivates
and/or destroys malignant cells with relatively little damage to normal
tissue.
Summary of the
Invention
... Herein, it is
discovered that high intensity magnetic fields applied in short pulses with
moderate frequencies, can be used to selectively destroy or otherwise inactivate
malignant cells within tissue of a living animal. Selective inactivation of
malignant cells within animal tissue subjected to a pulsed magnetic field is
accomplished without noticeable deterioration of gross characteristics of normal
tissue.
Detailed Description of a Preferred
Embodiment
It is found that subjecting
body parts containing cancerous tissue to a plurality of magnetic field pulses,
with characteristic frequencies above about 5 kHz and intensities above about 1
Tesla, will either arrest the growth of tumors or progressively reduce the
number of cancerous cells, resulting in remission of tumors... The magnetic
field in the coil is produced upon discharge of a bank of capacitors. The
capacitor bank is charged from a source, and when a switch is closed... an
oscillating current can be generated between the plates of the capacitors. The
oscillating current, in turn, generates a pulsed magnetic field which is
concentrated within the region bounded by the coil... Immediately subsequent to
closing the switch, an intense magnetic field is produced by current flowing in
one direction. As the current changes direction, the magnetic field changes
polarity... The oscillating current and, hence, the oscillating magnetic field
rapidly decreases after about ten oscillations dropping to a few percent of the
original magnetic field strength. Herein, magnetic field intensities refer to
the intensities of the initial peaks... The method is applicable to practically
any type of tissue and is believed applicable for treatment of most types of
malignancies... In each session, an animal is exposed to at least 1 and up to
1000 magnetic pulses. Generally a living animal would be subjected to at least
ten pulses at each therapy session and up to one hundred pulses. An animal will
be subjected to additional sessions until tumor remission is achieved...
Malignant cells are more susceptible to destruction and/or inactivation by a
pulsed intense electromagnetic field because the field may create eddy currents
that are unique to the tumor. These localized eddy currents may cause effects
that are deleterious to the viability and/or reproductive capability of the
tumor cells. Alternatively, there may be macromolecules unique to malignant
cells which are especially magnetically susceptible... Furthermore, treatment
with a pulsed magnetic field does far less damage to the natural immune system
than does radiation treatment or chemotherapy. Frequently, a patient who is
treated extensively with ionizing radiation and/or with chemotherapy will
experience an almost complete breakdown of the immune system. Subsequent to
treatment, the immune system may take up to a year to recover, particularly with
respect to immunity to viral infections. As a result, even if a patient is cured
of the malignancy by radiation and/or chemotherapy, he is subject to
debilitating disease or even death by infections to which his body would
ordinarily have built up immunity. With the magnetic treatment described herein,
here has been no evidence of major immune system
beak-down.
TABLE 2
Evaluation of the Growth of Rat Mammary Tumors
Following Multiple Exposures to a Rapidly Varying Magnetic
Field
Partial or Complete
Response
Total Total
Tumors
Tumor No.
of
Interruption Responding
Type
Tesla/kHz Tumors
of
Growth Shrinkage No.
in percent
DMBA 5T /
8kHz
8
2
6
8
100%
primary
NMU 5T /
8kHz
10 1
9
10
100%
primary
It can be seen from the above table that
the method of the present invention is useful for treating a variety of
malignancies, although the response varies according to the type of tumor.
Accordingly, the method has general applicability to malignancy
treatment.
Example 3
Twelve rats having primary DMBA-induced mammary
carcinomas were treated daily with a conventional Magneform machine. A primary
mammary gland carcinoma induced by a carcinogen, such as DMBA or NMU, is highly
virulent, as outlined in substantial detail in P. M. Guillino, et al., Journal
of the National Cancer Institute, Vol. 54, no. 2, February 1974. It is common
for such a tumor in a rat to increase in size by about 10 to 30 fold in about 30
days, and if left untreated almost invariably will ulcerate within about 45
days. Ten of the rats are treated daily with 20 pulses at 5 Tesla and 8 KHz.
Their tumor volumes on the 1st and 30th days are listed in with table 3
below:
TABLE 3
Test Tumor volume
(cm3)
Rat Day 1 Day
30
1. 1.60 1.95
2. 1.20
3.65
3. 2.10 1.20
4.
1.40 3.81
5. .90 .42
6. 3.00 3.81
7. .38
.45
8. 2.10 8.18
9.
6.79 8.88
10. 1.10
.85
It can be seen from the above table that after thirty
days the tumors were either diminished in size, stabilized, or at least
controlled relative to untreated tumors... The remaining two rats were treated
in an identical manner but at 1/4th the field intensity, i.e., 1.2 Tesla, 8 kHz,
20 pulses. One of these died on day 58 while the tumor size of the other had
decreased in size from 1.6 cm3 on day 1 to 1.4 cm3 on day
62. The rats generally appeared to exhibit normal behavior and appetite and did
not appear to lose weight. The fact that the rats did not die of infections
suggested that the immune systems functioned
normally.
Michael's Notes on Patent
4,665,898
This device produces the same type of
oscillating magnetic field as does my OMF Generator. The basic design of mine is
the same, with a capacitor (charged with high voltage) connected in parallel
with a coil by an electrically controlled switch (a xenon flash tube) to produce
a decaying oscillating magnetic field. This patents device varies from mine in
application only by the test subject being placed inside the coil, whereas mine
was used so that the coil rests on the test subject which is effected by the
lines of magnetic force emanating from the coil. Field force becomes less and
less with more distance from the center of the coil as is indicated by the field
force lines separating more. The results of test example 1 is a reduction of
live cancer cells (in test tube) of 32% of undifferentiated carcinoma and 29% of
embryonic carcinoma after 18 days. This was after 8 pulses of oscillating
magnetic field of 5 Tesla at 8 kHz on day 1. The results of test example 2 is
75% and 90% of treated rat mammary tumors (6 of 8 DMBA primary tumors, and 9 of
10 NMU primary tumors) shrunken after 20 pulses daily of OMF at 5 Tesla and 8
kHz for 6 days. The results of test example 3 is an average 86% reduction of
tumor size after 30 days (compared to a typical 20 times tumor growth after 30
days). Treatment was with 20 pulses OMF of 5 Tesla at 8 KHZ daily for 30 days.
Tumors were induced by injection of the DMBA chemical. The table below has
columns for the typical 20x size after 30 days and the percent reduction of the
treated tumors compared to the 20x size. It also shows the equally positive
lower intensity (1.2 Tesla) test results on one tumor with a resultant 96%
reduction.
TABLE 3
Tumor
Volume
(cm3)
typical size after 30
days percent
Rat Day
1 Day 30 if left untreated (x20
size) reduction
l.
1.60
1.95
32.
94%
2. 1.20
3.65
24.
85%
3. 2.10
l.20
42.
97%
4. 1.40
3.81
28.
86%
5. .90
.42
18.
98%
6. 3.00
3.81
60.
94%
7. .38
.45
7.6
94%
8. 2.10
8.18
42.
8l%
9. 6.79
8.88
13.6
35%
l0. 1.1
.85
22.
96%
average 86%
treatment with 20 pulses of 1.2 Tesla at 8 kHz for 30
days
11. l.6
1.40
32.
96%
[from:
http://www.cfsan.fda.gov/~comm/ift-omf.html]
U.S. Food and Drug Administration
Center for Food Safety and Applied
Nutrition
June 2, 2000
Kinetics of Microbial Inactivation for
Alternative Food Processing Technologies Oscillating Magnetic
Fields
Scope of Deliverables
This section reports the effects of magnetic fields on microbial
populations.
1. Definition, Description and
Application
Static (SMF) and oscillating (OMF) magnetic
fields have been explored for their potential as microbial inactivation
methods... an OMF is applied in the form of constant amplitude or decaying
amplitude sinusoidal waves. OMF applied in the form of pulses reverse the charge
for each pulse, and the intensity of each pulse decreases with time to about 10%
of the initial intensity (Pothakamury and others 1993). Preservation of foods
with OMF involves sealing food in a plastic bag and subjecting it to 1 to 100
pulses in an OMF with a frequency between 5 to 500 kHz at temperatures in the
range of 0 to 50 degrees Celsius for a total exposure time ranging from 25 to
100 milliseconds. OMF of intensity of 5 to 50 tesla (T) and frequency of 5 to
500 kHz (5000 - 500,000) was applied and reduced the number of microorganisms by
at least 2-log cycles (1/100th ). OMF of this intensity can be generated using:
(1) superconducting coils; (2) coils which produce DC fields or (3) coils
energized by the discharge of energy stored in a capacitor (Gersdof and others
1983). Inhibition or stimulation of the growth of microorganisms exposed to
magnetic fields may be a result of the magnetic fields themselves or the induced
electric fields. The latter is measured in terms of induced electric field
strength and induced current density.
2. Inactivation of Microorganisms
Table 1. Effect of magnetic
fields in microorganisms.
type of
field frequency
magnetic micro-
strength of pulse
field organism
Effect
Reference
12 tesla
6000 OMF
Streptococcus Cell population reduced Moore
(1985)
(1
pulse) Themophilus
from 25,000 cells/ml
to 970
in milk
7.5 tesla 8500 OMF Mold spores Population reduced from Hofmann (1985)
(1 pulse) 3,000 spores/ml to 1
Hofmann (1985) reported on the inactivation
of microorganisms with OMF in milk, yogurt, orange juice and bread roll dough.
According to Hofmann (1985) only 1 pulse of OMF was adequate to reduce the
bacterial population to between 1% and
.1%.
References
Hofmann G.A. 1985. Deactivation of
microorganisms by an oscillating magnetic
field.
U.S. Patent 4,524,079. Moore, R.L. 1979.
Biological effects of magnetic fields Studies with microorganisms. Can. J.
Microbiol.,
25:1145-1151
Gersdorf, R., deBoer, F.R., Wolfrat, J.C.,
Muller, F.A., Roeland, L. W. 1983. The high magnetic facility of the University
of Amsterdam, high field magnetism. Proceedings International Symposium on High
Field Magnetism. Osaka, Japan.
277-287
Pothkamury, U.R., Barbosa-Canovas, G.V., and
Swanson, B.G. (1993). Magnetic-field inactivation of microorganisms and
generation of biological changes. Food Technol.
47(12):8593
Michael's Notes: This papers test results
revealing effectiveness against bacteria and fungi/mold, and patent 4,524,079,
is what inspired me to create my own version of the mentioned device. The OMF
Generator I sell is an oscillating magnetic field generator (with an OMF of
decaying amplitude as Hofmann and Moore used) with a magnetic field strength of
around 6 Tesla and a frequency of around 5800 cycles per second (5.8 KHz).
Its electromagnetic coil is energized by the discharge of energy stored in a
capacitor. The experiences of myself and others with the OMF Generator are in
agreement with the scientific test results of Moore and Hofmann in that it
appeared effective against bacteria and mold (fungus) although our test medium
was human tissue instead of food. Their test results showed a 96% reduction of
streptococcus bacteria (at 6kHz/12T) and a 99.9% reduction of mold spores (at
8.5kHz/7.5T).
U.S. Patent
4,524,079
Inventor: Gunter A.
Hofmann
Date: June 18, 1985
Deactivation of Microorganisms by an
Oscillating Magnetic Field
Abstract
Material...
such as food products... is disposed within a magnetic coil and subjected to one
or more pulses of an oscillating magnetic field having an intensity of between 2
and about 100 Tesla and a frequency of between 5 and about 500 kHz. A single
pulse of the magnetic field generally decreases the microorganism population by
at least about two orders of magnitude. [1/100th]
Detailed
Description of a Preferred Embodiment
The magnetic
field in the coil is produced upon discharge of a capacitor. The capacitor is
charged from a source, and when a switch is closed... an oscillating current is
generated between the plates of the capacitor. The oscillating current in turn
generates an oscillating magnetic field which is concentrated within the region
bounded by the coil... Immediately subsequent to closing the switch, an intense
magnetic field is produced by current flowing in one direction. As the current
changes direction, the magnetic field changes polarity. The oscillating current
and, hence, the oscillating magnetic field rapidly deteriorates, with the field
intensity after about ten oscillations dropping to a few percent of the original
intensity. Herein, magnetic field intensities refer to the intensity of the
initial peaks... Herein pulse duration is considered to be 10 oscillations,
after which the substantially decayed field has a negligible
effect.
Example 1
A sample of
pasteurized milk is... inoculated with Streptococcus thermophilus at a
concentration of 25,000 bacterium/cm3... The milk is subjected to 1
pulse of a 12 Tesla, 6kHz, oscillating magnetic field... An aliquot of the milk
is plated on a standard plate. The colony count of the plate shows a
concentration of about 970 Streptococcus thermophilus per
cm3.
Example 2
350g of
plain 4% fat yogurt is opened, inoculated with Saccharomyces at a concentration
of 3,500 bacteria/cm3 and stirred thoroughly. The container full of
inoculated yogurt is placed centrally within the coil described above and
subjected to 10 pulses of a 40 Tesla, 416 kHz oscillating magnetic field. A
sample of the yogurt is plated on standard plates, and a count of the cultures
reveals a concentration of only about 25 Saccharomyces bacteria per
cm3 of yogurt.
Example 4
A prepackaged dough product... is thoroughly mixed with mold spores to
give a concentration of 3000 spores/cm3. The chopped rolls... was
centered in the above-described coil where it was subjected to l pulse of 7.5
Tesla, 8.5 kHz, oscillating magnetic field. A sample of the chopped rolls is
plated on standard plates, and a culture count shows a mold spore concentration
of only about 1 spore per cm3.
Michael's Notes on Patent 4,524,079
This device produces the same type of oscillating magnetic
field as does my OMF Generator. The basic design of mine is the same, with a
capacitor (charged with high voltage) connected in parallel with a coil by an
electrically controlled switch (a xenon flash tube) to produce a decaying
oscillating magnetic field. This patents device varies from mine in application
only by the test product being placed inside the coil, whereas mine is used so
that the coil rests on the test subject which is effected by the lines of
magnetic force emanating from the coil. Field force becomes less and less with
more distance from the center of the coil. The patents results of test example 1
is a 96% reduction of bacteria (from 25,000 to 970). The patents results of test
example 2 is a 99.3% reduction of bacteria (from 3,500 to 25). The results of
test example 4 is a 99.9% reduction of fungi spores (from 3000 to l ).
Quotes from Various
Electromedicine Patents
Patent 6,675,047
Electromagnetic-field therapy method and
device
Pulsed [electromagnetic] field therapy produces
a complex effect on the living organism, because it contributes to an
improvement in the energy metabolism, increases the mobility of lymph, enhances
the blood supply of capillaries, and, as a consequence, improves nutrition of
all tissues of the organism. The pulse field therapy liquidates stagnation of
energy in tissues, whereby painful sensations are eliminated. The pulse therapy
improves ion exchange on the level of cells, regulates the intracellular
pressure, this contributing to normalization of the overall
metabolism.
Patent 7,024,239
Pulsed electromagnetic
energy treatment apparatus and method
Electrotherapy
includes various means for applying an electric or electromagnetic field to a
wound area to facilitate growth and proliferation of new tissue, i.e., healing.
Application of external electrical and electromagnetic fields is now an
increasingly standard therapy for the treatment of non-union bone fractures, but
these devices have seen limited use in other areas of healing. The present
invention may also be utilized in other treatment areas where increasing the
rate of growth and proliferation of cells is essential, including the treatment
of burns and surgically implanted skin or soft tissue grafts, rehabilitation
medicine, post surgical repair, and neuronal/brain/spinal injury repair and
regeneration.
Patent 6,261,221
Flexible coil pulsed
electromagnetic field (PEMF) stimulation therapy system
PEMF therapy has been satisfactorily used in treating spinal fusion,
failed arthrodeses, osteonecrosis, and chronic refractory tendonitis, decubitus
ulcers and ligament, tendon injuries, osteoporosis, and Charcot foot. During
PEMF therapy, an electromagnetic transducer coil is generally placed in the
vicinity of the musculoskeletal injury (sometimes referred to as the "target
area") such that pulsing the transducer coil will produce an applied or driving
field that penetrates to the underlying damaged bone or other body
tissue.
Medical Hypotheses (1997) 49, pg
297-300
Targeting a key enzyme in cell growth: a novel therapy for
cancer
Abstract --- The enzyme ribonucleotide
reductase (RR) controls the synthesis of DNA precursors and thus plays a pivotal
role in cell growth. Since the free-radical-containing active-site of this
enzyme can be disabled by a lone electron, low-level direct electric current
should have an inhibitory effect on RR and, thus, on uncontrolled cell
proliferation. This hypothesis is strongly supported by the results of several
cancer electrotherapy studies reported over the years.
Introduction
Cancer is
uncontrolled cell growth. For a cell to divide, it must replicate its DNA
strand. The building blocks of this strand are in short supply in a healthy,
resting cell. However, the building blocks of a related molecule RNA are always
in great abundance since RNA is needed for many cellular functions. When a cell
is ready to divide, an enzyme called ribonucleotide reductase (RR) converts
building blocks of RNA into those of DNA. The enzyme RR is, thus, pivotal for
cell growth. Not surprisingly, the activity of this enzyme is tightly linked,
much more than that of any other enzyme, to neoplastic transformation and
progression (1).
A whole class of anti-cancer chemotherapeutic drugs,
hydroxy-urea being best known, is aimed at blocking the enzyme RR (2). However,
utility of such drugs is limited since inhibition of the enzymic activity is
only partial and undesirable side-effects are many.
Hypothesis
A novel way of
arresting the activity of this pivotal enzyme in cell growth is suggested by the
fact that the active site of RR contains a stable tyrosyl free radical which is
essential for its activity (13). Such free radicals can be neutralized/destroyed
by free-floating electrons -- easily available in the form of direct electric
current. Thus DC electrotherapy should result in inhibition of RR and cessation
of malignant cell proliferation. Low-level surface DC electrotherapy would act
selectively on cancerous growth since the concentration of the target enzyme RR
is exponentially higher in cancerous cells, as compared to healthy quiescent
cells (1). Metastasized cancer should also be treatable by direct current
electrotherapy since even in the metastatic state, irrespective of the organ
micro-environment, the biochemical mechanism of cell division involving the
enzyme RR, remains the same.
Experimental
evidence
The connection between low-level DC
electrotherapy and deactivation of enzyme RR is being proposed for the first
time. However, use of low-level direct electric currents to treat tumor --
without any clear understanding of the underlying mechanism -- has been reported
in scientific literature about ten times during the last four decades (4-13).
Three of these papers - the last one in 1985 - reported very encouraging
results. For example, in some experiments, there was total regression in 60% of
mice (4), an average of 88% tumor necrosis [destruction] in hamsters (5), and
98% reduction in tumor mass, also in hamsters (7). (It is strange that none of
these studies had any proper follow-ups.) The outcome of other studies was less
positive -- almost certainly due to poor choice of parameters.
Following
is a summary of these ten reports. (The electrode near the tumor is termed as
'active', the other one being called 'passive'.)
1. Humphrey et
al, 1959 (4)
ACTIVE Electrode: Copper or Zinc plate with
saline-solution-saturated sponge on unbroken skin over tumor.
PASSIVE
Electrode: Same, over ventral area.
BEST RESULTS (Total regression in 60%
mice): at cathode, with 3 milliamperes at 3 V, 4.8 hours per day for 21
days.
2. Schauble et al, 1977 (5)
ACTIVE Electrode: Silicone covered
steel needle - exposed tip implanted.
PASSIVE Electrode: Wire-mesh with
electrode paste and saline-dampened sponge - over chest skin.
BEST RESULTS
(88% Necrosis): at positive electrode with 3 mA at 1.5 V, 1 hour per day for 4
days.
NOTE: Necrosis was also observed when active electrode was made
negative.
3. Habal 1980 (6)
Poor results with 0.5 µA at 1.5 V, for 12 days continuous, using an implanted
device.
4. David et al, 1985 (7)
ACTIVE Electrode: Silicone covered
Steel or Platinum-Iridium (70:30) needle - exposed tip implanted.
PASSIVE
Electrode: Aluminum foil plate with conducting paste - over shaved underbelly.
BEST RESULTS (98% Reduction in tumor mass): at either electrode, with 2.4 mA
at less than 3 V, for 1 hour per day for 5 days.
5. Marino and Morris et
al, 1986 (8)
Both Electrodes ACTIVE: Insulated Platinum - except for the
implanted tips - at foci of tumor.
BEST RESULTS (Total regression in 43% of
primary tumors): with 2 mA at about 3 V, 1 hour per day for 3 intermittent
days.
6. Morris and Marino et al, 1992 (9)
Both Electrodes ACTIVE:
Platinum needles - implanted in tumor.
BEST RESULTS (Reduction in tumor mass
without improved survival): with 20 mA at 8-10 V, for 15 minutes once.
7.
Miklavki et al, 1993 (10)
ACTIVE Electrode: Platinum-Iridium (90:10), Gold,
Silver or Titanium needle tip implanted.
PASSIVE Electrode: Same, placed
subcutaneously the whole length, near tumor.
BEST RESULTS (About 70%
necrosis): at cathode, with 0.6 mA at unspecified volts, for 1 hour once.
NOTE: "Field" electrotherapy, by placing both electrodes subcutaneously for
their entire length, on either side of tumor, also produced similar
necrosis.
8. Griffin et al, 1994 (11)
ACTIVE Electrode: Gold needle -
implanted.
PASSIVE Electrode: Copper plate with conducting gel - beneath the
animal.
BEST RESULTS (Regression proportional to charge passed): at anode,
with 1-4 mA at 1-16 V, for 30-90 min. once.
9. Taylor et al, 1994 (12)
ACTIVE Electrode: 4 parallel brass plates, vertically mounted, in a
specially designed oesophageal tube.
PASSIVE Electrode: Large plate with
saline-soaked pad on human patient's back.
BEST RESULTS (Oesophagus tumor of
one patient regressed completely at the primary site): with 20 mA at 7 V, at
each of four anodes, for 1 hour. Three treatments over 4+1/2 month
period.
10. Miklavki et al, 1994 (13)
ACTIVE/PASSIVE Electrodes: Gold
needles, placed subcutaneously the whole length, on either side of tumor.
BEST RESULTS (Tumor growth slowed by a factor of 3): with 1.0 mA at
unspecified volts, for 1 hour, applied once.
NOTE: No correlation was
observed between the amount of deposited electrode material (gold) and
anti-tumor effect.
Discussion and conclusion
Both positive and negative results of the published low-level
electrotherapy studies can be adequately explained by the posited
enzyme-mediated mechanism. Various aspects of these reports is being discussed
in these sections:
Positioning & Polarity of
Electrodes
If deactivation of the enzyme RR is the
dominant mechanism underlying the efficacy of electrotherapy, then it should not
matter whether electrodes are implanted or on the surface -- as long as the
tumor is in the path of the current. Only in study #1 (4) were both electrodes
placed on unbroken skin, and it reported one of the better results. Beside being
non-invasive, surface electrodes also minimize electrochemistry and its
attendant toxicity. Similar reasoning would suggest that the polarity of the
electrodes is inconsequential. Almost all electrotherapy studies where
beneficial results were obtained, confirm this. Results of "field"
electrotherapy experiments, where electrodes were implanted on either side of
tumor (10,13) also show that polarity of electrodes is immaterial, and that
electrode-electrolyte interactions are of little
significance.
Electrode Metal
Dissolution
If the primary mechanism of electrotherapy
involves inhibition of enzyme RR, then electrode metal deposition should have
little or no influence on the beneficial outcome. Study 10 (13) has clearly
shown that this is so. The fact that different electrode materials produce very
similar results, further indicates that electrodes act merely as electron
conductors. Thus, virtually all the observed facts are in accord with the
proposed mechanism involving the deactivation of the free-radical-containing
active site of RR. Furthermore, a recent experiment has shown that the
concentration of enzyme RR decreases and cell growth ceases when direct electric
current is passed through the tumor (15). The proposed hypothesis, thus, is on
the verge of being proved.
This novel way of arresting cell growth can be
the foundation of a cancer therapy that is non-toxic, non-invasive,
site-specific, low-cost and easy to administer. The current cancer treatments
are called "slash, burn & poison" by oncologists themselves, and are mostly
empirical in nature. The gentle electrotherapy, on the other hand, would be
deductively scientific with potential to cure most
cancers.
References
1. Weber, G.
(1983) Biochemical strategy of cancer cells and the design of chemotherapy.
Cancer Res. 43, 3466-3492.
2. Cory, J.G., and Cory, A.H. (1989) Inhibition
of ribonucleoside diphosphate reductase activity. International encyclopedia of
pharmacology and therapeutics. New York: Pergamon Press, pp 1-16.
3.
Graslund, A., Ehrenberg, A., and Thelander, L. (1982) Characterization of the
free-radical of mammalian ribonucleotide reductase. J. Biol. Chem. 257,
5711-5715.
4. Humphrey, C.E., and Seal, E.H. (1959) Biophysical approach
toward tumor regression in mice. Science 130, 388-390.
5. Schauble, Habal,
and Gullick, (1977) Inhibition of experimental tumor growth in hamsters by small
direct currents. Arch. Pathol. Lab. Med. 101, 294-297.
6. Habal, M.B. (1980)
Effect of applied d.c. currents on experimental tumor growth in rats. J. Biomed.
Mat. Res. 14, 789-801.
7. David, Absolom, Smith, Gams, and Herbert, (1985)
Effect of low level direct current on in vivo tumor growth in hamsters. Cancer
Res. 45, 5625-5631.
8. Marino, A.A., Morris, D., and Arnold, T. (1986)
Electric treatment of lewis lung carcinoma in mice. J. Surg. Res. 41, 198-201.
9. Morris, D.M., Marino, A.A., and Gonzalez, E. (1992) Electrochemical
modification of tumor growth in mice. J. Surg. Res. 53, 306-309.
10.
Miklavki, D., Sersa, G., Kryzanowski, M., Novakovi, S., Bobanovi, Golouh, and
Vodovnik, (1993) Tumor treatment by direct electric current - tumor temperature
and pH, electrode matterriial and configuration. Bioelectro. B. 30, 209-220.
11. Griffin, D.T., Dodd, N.J.F., Moore, J.V., Pullan, B.R., and Taylor,
(1994) The effects of low-level direct current therapy on a preclinical mammary
carcinoma: tumor regression and systemic biochemical sequelae. Br. J. Cancer 69,
875-878.
12. Taylor, T.V., Engler, P., Pullan, B.R., and Holt, S. (1994)
Ablation of neoplasia by direct current. Br. J. Cancer 70, 342-345.
13.
Miklavki, D., Fajgelj, A., and Sersa, G. (1994) Tumor treatment by direct
electric current: electrode material deposition. Bioelectro. B. 35, 93-97.
14. Nordenstrom, B.E.W. (1985) Electrochemical treatment of cancer. Ann.
Radiol., 43, 84-87.
15. Yen, Y., and Chou, C.K., City of Hope Medical
Center, Duarte, CA., USA (personal communication).
Michael's Comments: The referenced studies
were able to acheive 3ma of electrical current with low voltage (~3v) because
the electrodes were directly opposite tumors on small mice. On larger animals it
is certain that more voltage will be necessary to acheive 3ma current because
more living tissue between electrodes presents more resistance. The formula for
determining current (I=V/R) shows that with more resistance, more voltage is
necessary to acheive the same current. Therefore, our DC Electrifier uses five
9v batteries for a total of 45 volts which may be necessary to acheive 3ma
current. The main control on the unit adjusts the amount of current between 1
and 5mA, and the output current will trigger a red light to come on when 3ma is
acheived. It is the current which does the work, not the
voltage.
ANTIOXIDANT EFFECTS OF ULTRA-LOW
MICROCURRENTS
Alfred J. Koonin, M.B., Ch, B., Ph.D.,
FRCS
Exerpt from: http://www.eprtech.com/ANTIOXIDANT%20EFFECTS.htm
To see if these ultra-low currents could work as an antioxidant, the
model chosen was chronic skin wounds. The reason for this was that most of these
lesions are found in debilated patients with poor immune systems who probably
have a high concentration of free radicals. Further, the wounds themselves are
generally necrotic and infected with poor healing potential again indicating a
high concentration of free radicals in the local area. The idea was to isolate
the injured area as part of the circuit and thereby infuse a steady stream of
electrons through the area with as little resistance as possible. The resistance
would be reduced by using a low level current and by increasing the diameter of
the conductor. Also, the frequency of the current would have to be low in order
to prevent the electrons from traveling in short bursts. A low frequency would
allow the electrons to move in a steady stream.
Method
A device was used
that produced a current range of 3mA down to .1mA. The frequency used produced a
cycle lasting approximately 23 minutes. The device was designed to switch the
direction of current flow half way through the cycle. The device runs on a
rechargeable battery producing a square wave bipolar current with a Voltage
ranging between 5V up to a maximum of 40V. The Voltage range will vary
proportionately with the resistance in the tissues. The device will not function
if the range goes beyond 40 Volts. The electrodes are applied in two layers
using tap water as the conducting medium. Water is a very poor conductor of
electricity, but the minerals in tap water are sufficient to carry the current
into the tissues. Also, the wraps cover a large surface area thus reducing
resistance and allowing an optimum number of electrons to flow freely into the
tissues.
Patients were treated for approximately 3« hours per day, five days
a week until the lesion had healed. A twelve-week maximum was allowed for
healing to take place. All patients were in-patients and were on wound care
treatments for at least three months prior to this study, with no observable
improvement in their condition. The 25 patients treated had lesions present for
an average of 18.5 months.
For approximately 23 minutes per day the subjects
were wrapped with spongy bandages, soaked in water, above and below the wound to
make the sites readily receive the electric current later. Conductive silicone
electrodes were then wrapped over these areas and attached to the device with
stud clips. For the first cycle (23 minutes) the device was set at a current
output of 3 mA. For the subsequent eight cycles of treatment (approximately
three hours) the device was set at an output of .4mA. Twenty-five chronic wounds
were treated. These were present for a period ranging from 3 to 60 months and
did not respond to standard therapy. Ages of the patients in the study varied
from 20 to 85 years old. Twenty-three of the lesions were stage III or IV. 92 %
of the lesions were stages III or IV. The age of the lesions varied from 6 to 60
months with an average of 18.5 months. 100% of the lesions healed in an average
of 48 hours of treatment, i.e. an average of 16
days.
Electric current helps diabetic foot ulcers
heal
NEW YORK, Jul 11 2001 (Reuters Health) - A device that
delivers high-voltage electric stimulation to the skin can help diabetic foot
ulcers heal, preliminary study findings suggest.
People with
diabetes may develop foot ulcers as a result of poor circulation and a reduced
ability to fight infection. Usually, ulcers are treated by cleaning and dressing
the wound to keep it moist and resting the affected limb, but in some cases,
damage can be severe enough to require amputation.
According to a report in
the June issue of the Archives of Physical Medicine and Rehabilitation, patients
who used an electric stimulation device in addition to standard treatment were
more likely to heal.
The study of 35 diabetic patients compared high-voltage,
pulsed galvanic electric stimulation every night for 8 hours with an inactive
placebo treatment that felt the same but delivered no current. Patients also
underwent weekly removal of dead tissue, topical treatment and rest.
Over 3
months, 65% of patients who received electric stimulation healed, compared with
35% of patients in the placebo group.
It is not clear how electric
stimulation aids in wound healing, but the researchers suggest that it may
enhance blood flow and immune system cell function.
"It's not a silver
bullet," study author Dr. Lawrence A. Lavery of the University of Texas Health
Sciences Center in San Antonio, told Reuters Health, noting that the device
should be used in combination with other measures. However, he added, "it is
more promising than some pharmaceuticals that I've seen."
There was no
difference in the amount of time it took for wounds to heal among groups, the
study found.
Still, "the results of this study are quite promising and
compare favorably with several recent reports in the medical literature on wound
healing in persons with diabetes mellitus," Lavery and colleagues
conclude.
They add that larger trials should be conducted to further
investigate whether electric stimulation can help diabetic foot ulcers to
heal.
SOURCE: Archives of Physical Medicine and Rehabilitation
2001;82:721-724.
Electric Current Helps Wipe Out Liver Tumours
by Nic Rowan
Thursday, November 08, 2001 2:06 p.m. EST
-
- - - -
ADELAIDE, Australia (Reuters Health) - Surgeons here
who pioneered the use of electrical current to destroy liver tumours say they
are optimistic that the treatment could be used for tumours of the pancreas and
kidney as well. The treatment, called electrolysis, involves placing electrodes
into liver tumours and surrounding tissue. A small electric current is then
passed through the electrodes to destroy the tissue. In some cases, affected
parts of the liver are removed surgically.
The leader of the surgical team
investigating the treatment, Professor Guy Maddern of Adelaide University, told
Reuters Health that the method causes a change in the acidity of the tissue and
"poisons the tumour."
"It is less destructive than surgical removal of the
tumour, and can be used to treat tumours that are awkwardly located, such as
next to large blood vessels," he added. Maddern and his colleagues have treated
10 patients, with follow-up ranging from 6 to 43 months. Nine of the patients
had bowel cancer that had spread to the liver, and one had cancer that
originated in the liver.
In order to be included in the study, patients had
to have no other untreatable tumour outside the liver, and to be fit for major
surgery. All patients, said Maddern, had extensive disease in the liver.
Eight of the patients show no evidence of residual tumour at the treatment
site. Five of these eight patients have developed new areas of tumour spread,
while three have no evidence of new cancer growth.
"In any case, after
surgical intervention without electrolysis, 60% of patients would be expected to
develop new disease," Maddern said. "We are trying to increase the percent who
don't get new disease."
When added to surgery to remove a tumour, Maddern
noted, electrolysis increased the percentage of patients who were treatable with
surgery from 20% to 25%. "We have been developing this technique for 5 years. We
are now ready to move forward and are considering tumours of the pancreas and
kidney," Maddern told Reuters Health. "They will be the next
step."
Alternative cancer treatment with few side effects: The Electro
Carcinoma Therapy (ECT)
Original
article in german: http://www.naturmednet.de/krebs/tumor.ect.html
The
Electro-Carcinoma Therapy is a form of tumor treatment that is hardly known. So
far, some empirical values and a first study are present. The Institute for
Natural Health Methods in Marburg Germany uses ECT.
The principle: A weak
direct current is applied to the tumors, which can shrink, as a direct
consequence and even disappear completely.
From China came
the first results of a larger case study which uses the ECT treatment with over
10,000 patients in the period of 1987 to 2000. One of the central results: in
just over 30% of the cases, it brought about the dissolution of the tumors, and
in somewhat more than 40%, to the reduction of the tumor. The individual success
values hang thereby, among other things on the kind of tumor and size as well as
the stage of the illness.
The Chinese medical profession apply the energy in
particular by means of platinum wire electrodes, in the form of needles,
injected directly into the tumors. In contrast; the Marburg Institute works
almost exclusively with plate formed metal electrodes applied to the skin. "the
use of plates is gentler, possesses a higher acceptance with the patients and is
just as effective as the therapy with needles", explains Dr. Bernhard Weber,
head of the institute. First intermediate results of the local treatments seem
to confirm the results of the Chinese study.
The Electro-Carcinoma
Therapy is a local, low side-effect procedure that can be treated on an
outpatient basis. In the two to three hour treatment, energy flows through the
tumor. Some patients need only two or three sessions before the tumour will
"melt", others need more. With the help of a special computer monitor program
and controls, the physician controls the treatment and observes the procedures
in the body and the growth. The medical skill lies in being able to place the
electrodes in the correct location and setting of the optimal amperage - this
must be different depending upon tumor size, density and type.
ECT can
and should be used, depending upon illness, together with other forms of
treatment. In order to control the formation of secondary growths (metastases)
with malicious tumors, Dr. Weber advises to combine the use of ECT with radio
and/or chemotherapy. ECT does not replace good conventional therapy
possibilities; on the other side ECT can be a new therapeutic chance where
conventionally difficult or hardly treatable tumors and secondary growths are
present.
ECT is suitable for both surface as well as more deeply located
tumours, explains the Institute. Secondary growths in bones cannot be treated as
effectively with this method. Even if the tumor has already been pre-treated
with irradiation or chemotherapy, the Electro Carcinoma Therapy can still be
used.
Further information:
Institut fr Naturheilverfahren &
Naturheilkunde-Tagesklinik mit Schmerzambulanz
(Institut for natural health
method & naturopathy outpatient hospital with pain clinic)
Contact: Dr.
Bernhard Weber, email: b.weber@firemail.de
Uferstr. 1, 35037 Marburg,
Germany
Tel: +49 6421 68430; FAX: +49 6421 684350
Literature on
ECT:
Dr. med. Rudolf Pekar: Die perkutane Bio-Elektrotherapie bei Tumouren
(The percutaneous bio electrical therapy with tumours). Vienna, Munich, Berlin
1996.
Dr. med. Rudolf Pekar/Dr. med. Nikolai N. Korpan: Cancer. Vienna,
Munich, Berne 2002.
Source:
http://www.klinik-st-georg.de/englisch/ELEKTRO.HTM
Quote:
Electro
Cancer Treatment (ECT)
I. Introduction
Electro medicine has been widely
used for many years, especially in orthopedics where it has been used for
regeneration, i. e., to increase the healing process in broken bones (1) and
pain purposes. In Oncology, however, the use of electromedicine (ECT) is
relatively new and stems from research investigations of Pekar (2) and
Nordenstrom (3). Since 1987, St. George Hospital has treated hundred of patients
with this method of treatment. Direct current can be directed into tumorous
tissue (skin metastases, lymph node metastases or isolated organ metastases)
through the application of electrodes. If the total amount of direct current is
high enough, this procedure results in the destruction of cancerous cells and in
extreme cases, no necrotization.
II. Physical-chemical principles of
ECT
As soon as direct current is connected to the electrodes, different
electrochemical reactions influence the pH-value and can cause electrolysis of
tumor tissue. Depolarization of the cell membranes changes the cellular
environment forcing the tumor cells to be gently destroyed. Consequence of this
process is the interruption of certain functions within the cancerous cells,
which in turn, can lead to the destruction of these cells. Tumor tissue is more
susceptible to damage from direct current than normal tissue, thus allowing the
destruction of cancerous cells to occur when direct current is applied directly
to the malignant tissue. The body `s own catabolic processes remove the
destroyed malignant tissue from the body. It is also possible that through this
process the immune system starts fighting all other cancer cells within the
body. Once ECT or Galvano (as it is commonly known) treatment is successfully
completed, the cancerous area heals and is replaced with scar
tissue.
III. What types of tumor are suitable for ECT?
ECT is suitable
for all types of superficial or deep seated tumors, which can be reached by
needle electrodes. Specifically, however, are:
- small breast carcinomas or
isolated axiilllaaary, supraclavicular and thoracic nodes.
- all tumors of
the ENT area, especially after radiation or chemotherapy.
- skin carcinomas
e. g. Basaliome, Spinoccelllllular carcinoma, Melanoma etc.
- gynecological
carcinomas
- soft tissue tumors
IV. Special form of ECT using
cytostatic substances (Iontophoresis)
The destructive effect of the direct
current on tumorous tissue can be enhanced by the simultaneous administration of
cytostatic substances, for example, Mitomycin, Adrimycin, Epirubicin and
Cis-Platinium. Most cytostatic substances are positively charged, which when
inserted onto the anode in an electrical field directed through tumorous tissue
move to the cathodes (iontophoresis movement). In this way, cytostatics can be
introduced into the tumorous tissue in a very targeted and concentrated manner.
This method can be more effective on the tumor side than standard systemic
chemotherapy or local cytostatic perfusion. Cytostatic substances are best
applied to hollow organs, for example, esophagus, bladder, stomach and rectum.
The membrane potentials are changed so much by the current that the cells open
and absorb cytostatic substances more rapidly.
V. How is the treatment
carried out?
Normally the treatment is carried out under local anaesthetic
and on an outpatient basis. The size of the tumor determines how many needle
electrodes are required, however, a minimum of 2 are always used. These are
introduced into the tumor through the skin. The electrodes should not be further
than 1.5cm apart. The minimum required electric field must be 35 coulombs/ml
although up to 90 coulombs/ml are normally used. During the treatment, the
patient will experience a slight pressure pain or a slight tingling in the
treated area. Direct current brings about long lasting pain relief because it
inhibits the activity of sensory nerve fibers. Therefore there is no pain after
treatment. However because the cancerous tissue is being destroyed through this
method of treatment, it is normal that inflammation occurs for a couple of days
afterwards. The cancerous tissue is broken down naturally, which when eliminated
from the body is replaced by scar tissue. Superinfections rarely occur. ECT
replaces operations and radiation treatment. Judging by the very positive
therapy results, it can be assumed, that ECT will become an important form of
treatment for malignant diseases.
Literature
-
Senn E., Electro therapy, Thieme-Verlag - Pekar R., Percutaneous galvano therapy
of tumors, Verlag W.Maudrich, Vienna-Munich-Bern
- Nordenstrom BEW, The
European Journal off Surgery, Suppl. 577, Pg 93-109 Scandinavian University
Press
- Douwes F. R., The basics of electrochemical cancer treatment
1994
- Szasz. A., Advanced alternative medicine AAM-Series
- Pleasnicar
A., Electric treatment of human melanoma skin lesions with low level direct
current. The European Journal of Surgery, Suppl 574, Pg 45-49. Scandinavian
University press.
- Yunqin Song, Electrochemical treatment in the treatment
of malignant tumors on the body surface. The European Journal of Surgery, Suppl
574, Pg 41-43. Scandinavian University Press.
- Kuanhong Quan, Analysis of
the clinical effectiveness of 144 cases of soft tissue and superficial malignant
tumors treated with electrochemical therapy. The European Journal of Surgery,
Suppl 574, Pg 37-40. Scandinavian University
Press.
STUDIES ON THE EFFECT OF MEDIKZAP
AND NE 555 DEVICES USED IN NATURAL MEDICINE ON THE CANDIDA ALBICANS FUNGUS CELLS
Laboratory of Microbiology Diagnostics Clinical
Hospital no. 1
ul. Staszica 16, 20-081
Lublin, Poland
Abstract
The aim of
the study was to evaluate the effect of two positive off-set type current
generating by devices, available on the natural medicine market, on the Candida
albicans (fungus cells). In the course of the study, broth cultures of Candida
albicans were subjected to the influence of these two devices for a period of 10
days. Every day, the culture density and growth on an agar medium were
determined. The effects of each of the two devices on Candida albicans cells
were found to be
different.
Conclusion
There
are many cleansing devices available on the natural medicine market but their
effect on specific micro-organisms is different. This assumption was confirmed
by our in vitro studies on the effect of two different devices. Our analysis of
both Medikzap and NE 555 effects on Candida albicans cells has proved a greater
efficacy of Medikzap device in fungi control than that of the NE 555 device. The
NE 555 device was proved to have a static effect on Candida albicans cells but
it does not eliminate them completely.
[read full
report]
Ultra-low microcurrent in the
management of diabetes mellitus, hypertension and chronic wounds: Report of
twelve cases and discussion of mechanism of action
http://www.medsci.org/v07p0029.htm
Abstract
Oxidative
stress plays a major role in the pathogenesis of both types of diabetes mellitus
and cardiovascular diseases including hypertension. The low levels of
antioxidants accompanied by raised levels of markers of free radical damage play
a major role in delaying wound healing. Ultra-low microcurrent presumably has an
antioxidant effect, and it was shown to accelerate wound
healing. The purpose of the study is to investigate the efficacy of ultra-low
microcurrent delivered by the Electro Pressure Regeneration Therapy (EPRT)
device (EPRT Technologies-USA, Simi Valley, CA) in the management of diabetes,
hypertension and chronic wounds.
The EPRT device is an electrical device
that sends a pulsating stream of electrons in a relatively low concentration
throughout the body. The device is noninvasive and delivers electrical currents
that mimic the endogenous electric energy of the human body. It is a
rechargeable battery-operated device that delivers a direct current (maximum of
3 milliAmperes) of one polarity for 11.5 minutes, which then switched to the
opposite polarity for another 11.5 minutes. The resulting cycle time is
approximately 23 minutes or 0.000732 hertz and delivers a square wave bipolar
current with a voltage ranging from 5V up to a maximum of 40V. The device
produces a current range of 3 mA down to 100 nA.
Twelve patients with long
standing diabetes, hypertension and unhealed wounds were treated with EPRT. The
patients were treated approximately for 3.5 h/day/5 days a week. Assessment of
ulcer was based on scale used by National Pressure Ulcer Advisory Panel
Consensus Development Conference. Patients were followed-up with daily
measurement of blood pressure and blood glucose level, and their requirement for
medications was recorded. Treatment continued from 2-4 months according to their
response. Results showed that diabetes mellitus and hypertension were well
controlled after using this device, and their wounds were markedly healed
(30-100%). The patients either reduced their medication or completely stopped
after the course of treatment. No side effects were reported.
Patients and Methods
The device is noninvasive and
delivers electrical currents that mimic the endogenous electric energy of the
human body. The device produces a current range of 3 mA down to 100 nA
[.0001mA]. Electrodes are applied in 2 layers, and tap water is used as the
conducting medium. The wraps cover a large surface area, thus reducing
resistance and allowing an optimum number of electrons to flow freely into
tissues.
The EPRT at a setting of 100 nA is delivering 8.129x10 electrons
(14) per cycle. But as this amount is being delivered over a 23 minute period
(at rate of 6x10 (11) electrons per second) this behaves as a pressure instead
of a jolt. This steady stream of electrons is what makes the EPRT a super
antioxidant and not only does this correct malalignments in the cells electrical
system but it also eliminates free radicals and then stimulates the mitochondria
to produce ATP [for cellular energy via the breakdown of
glucose].
Patients and treatments
Case 1: The first
patient was a 74 year old female with poorly controlled non-insulin- dependent
diabetes, hypertension, and hypercholesterolemia. She was seen with vomiting,
diarrhea and gangrene of second toe on left foot. Two weeks prior to admission,
the patient had sustained fall in the bathroom resulting in a left ankle
fracture with vomiting and diarrhea for seven days. The patient was treated with
metformin and augmentin. Upon examination, the patient was afebrile with stable
vital signs, and femoral pulses were present bilaterally. Popliteal and pedal
pulses were absent bilaterally with poor capillary refill. The left foot was red
and inflamed up to and including the medial malleolus. The lateral aspect of the
great toe and second toe turned black. Laboratory investigation revealed
elevated blood glucose (17.9 mmol/L) and hyponatremia (Na+ 128 mEg/L). The
patient underwent a medial forefoot amputation as part of her management. Within
28 days after surgery, the 4th and 5th toes become discolored, dusky purple and
black. The patient also developed a large blood blister over her heel. Vascular
opinion was for a below knee amputation. The patient was self- discharged
against medical advice. The patient was started on treatment by Electro Pressure
Regeneration Therapy device (EPRT) while she was in hospital. She continued
daily treatments on the EPRT device at home, along with a diabetic diet. The
left foot continued to improve and heal, and her remaining gangrenous toes
eventually fell off. Her blood pressure at admission was 166/53 with use of
Lisinopril, which was dropped and eventually ceased as her BP continued to drop;
146/68, 129/64, 144/67 in second, third and fourth weeks after treatment, and to
128/66 during 6th to 8th weeks post-treatment while the patient was on no
medication. Her blood sugar was improved and HbA1c was dropped from 9.8 before
treatment to 7.6, 6.5, 5.9 and 5.5 during 9 months after commencement of
treatment. The patient eventually stopped diabetic and hypertensive medications.
To date her HbA1c remains below 6 on diet alone. [HbA1c is a substance in red
blood cells that is formed when blood sugar (glucose) attaches to it. This
patient dropped 23% blood pressure and 44% blood sugar.]
Case 2: The
second patient was a 65 year old male with a long history of non insulin
dependent diabetes and hypertension. Diabetic neuropathy had affected his feet
and he could not feel the shoe rubbing. A small superficial ulcer developed on
his 5th toe which became infected and subsequently, the 5th toe was amputated.
His condition rapidly deteriorated and he developed necrotizing fasciitis and
osteomyelitis. Consequently, he had surgery removing tendons, skin and the
capsular linings of joints from his right foot. The patient was discharged after
ten weeks in hospital with a large, infected, open wound requiring community
nurses to do wound management. The patient was treated by the Electro Pressure
Regeneration Therapy device; the wound was healed completely without further
management and the diabetes was well controlled. HbA1c dropped from 7.3 to 6.6
after treatment. His blood pressure was 202/99 before the treatment, which was
dropped to 155/73 after two weeks. His blood pressure continued within normal
range with the use of the Electro Pressure Regeneration Therapy device 2-3 times
weekly.
Case 3: A 70 year old female was diagnosed with hypertension,
epilepsy osteoarthritis and rheumatoid arthritis. Her blood pressure was 147/84
which was dropped to 138/72 three weeks after the treatment with the Electro
Pressure Regeneration Therapy device. She continued using the EPRT device twice
weekly and her blood pressure was under control without the use of
antihypertensive medications.
Case 4: A 77 year old female with
hypertension, hypercholesterolemia, hypothyroidism, and type 2 diabetes (NIDDM)
was treated with the Electro Pressure Regeneration Therapy device. Her blood
pressure before treatment was 158/81 which was dropped to 125/65 after 1 week.
Her blood pressure continued to be normal with use of the EPRT device despite
discontinuation of antihypertensive medications. HbA1c was 7.8 before treatment
which decreased to 6.9 and continued to be low during one year
follow-up.
Case 5: A 67 year old female with hypertension and
osteoarthritis was treated with the Electro Pressure Regeneration Therapy
device. Her blood pressure was 157/91 which dropped to 149/86 after 3
weeks.
Case 6: A 70 year old female with hypertension, fibromyalgia,
hepatitis, hypercholesterolemia, tuberculosis and a stroke was treated with the
Electro Pressure Regeneration Therapy device for her hypertension. Her blood
pressure was 134/84 before treatment which was dropped to 117/73 within 4 weeks
after treatment despite discontinuation of her antihypertensive
medication.
Case 7: A 75 year old female with hypertension and benign
postural vertigo was treated with the Electro Pressure Regeneration Therapy
device. Her blood pressure was 157/86 before treatment, which was dropped to
138/76 and continued within normal limits while receiving one treatment per
week.
Case 8: A 53 year old female with type 1 diabetes (IDDM) from the
age of 12, suffered renal failure as a result of her diabetes and underwent a
kidney and pancreatic transplant in 1994. She also has hypercholesterolemia,
left ventricular failure, renal failure and a history of a coronary artery
bypass graft. She then started treatment with the Electro Pressure Regeneration
Therapy device. While she is not considered to currently have diabetes her HbA1c
dropped over the time period she was receiving treatments from 5.4 to 5.1. This
was matched by her Blood Sugar Level (BSL) which also stabilized while she was
receiving treatment over this period of time.
Case 9: A 32 year old
female with type 1 diabetes (IDDM) and no other concurrent health problems was
treated with the Electro Pressure Regeneration Therapy device. She received 8
treatments over a two week period. HbA1c before treatment was 8.1 and was
dropped to 7.1 after treatment. Her insulin requirement was also
reduced.
Case 10: A 59 year old female with type 2 diabetes (NIDDM),
hypertension, fibromyalgia, chronic active hepatitis, and Bowens disease was
treated with the Electro Pressure Regeneration Therapy device. Her blood sugar
was normalized and HbA1c dropped from 7.2 to 6.3 after the treatment. Her HbA1c
showed a slight increase to 6.4 within three months after therapy was
discontinued.
Case 11: A 70 year old female with type 2 diabetes (NIDDM),
osteoarthritis, chronic pain and multiple operations was treated with the
Electro Pressure Regeneration Therapy device. Her average Blood Sugar Level
(BSL) before treatment was 9.8, and dropped to 7.4 and 7.1 after three and six
months of treatment. She was treated twice weekly with the EPRT
device.
Case 12: A 68 year old male with type 2 diabetes (NIDDM),
hypertension, stroke, chronic pain and polio was treated with the Electro
Pressure Regeneration Therapy device. HbA1c before treatment was 7.8, which was
dropped to 6.6 during treatment. He was treated three times per week most weeks
during a six month period. Upon discontinuation of therapy HbA1c increased to
7.8.
United States Patent 5,133,352
Lathrop , et al. July 28, 1992
Method for Treating Herpes
Simplex
Abstract
The present invention
provides an apparatus and method for treating infectious skin conditions, such
as Herpes Simplex 1 and 2. By the application of an electrical field and current
to the area of the manifestation of the disease on the body there is activated a
reaction at the cell level to combat the virus and disrupt its attack on the
healthy cell structure. The present method comprises a direct application of a
low voltage direct current, low amperage stimulation to the skin about the
infected location for a few seconds every hour for a length of time sufficient
to prevent formation and/or heal the resultant lesion.
Examples
and Methods of Treatment
86 men and women between the ages of 19 and
37 participated in the study over a period of 3 months.
Subjects were placed
in one of 3 groups as follows:
Group One: 23 control
subjects. These received no electrical stimulation and reported onset, progress,
and resolve of their lesions on a daily basis.
Group Two: 42
subjects. These were seen in a medical clinic with their electrical treatment
supervised by a medical doctor. These patients took no drugs and were treated in
the clinic commencing with the onset of each lesion and 4 times a week until the
lesion resolved.
Group Three: 21 subjects. These were each
issued a small electrical stimulation device (the same as the Herpes
Zapper) and were told to always keep them handy. They
were also told to be acutely aware of the onset of the next occurrence of
itching, tingling, pain, or ache in the area. Once they noticed oncoming
symptoms they were told to "use the electrical stimulator to make contact with
the potential lesion site for 15 seconds. Continue this procedure once per hour
for 8 hours without interruption on the first day of recognition of preliminary
symptoms." They were also told to continue this procedure until the lesion
resolved itself.
All of the subjects in this study suffered from either
Herpes Simplex 1 (mouth herpes) or 2 (genital herpes). Prior onset of the
disease ranged from 1.5 to 5 years.
RESULTS
Comparison of Treatment Procedures
Herpes Simplex 1 Herpes Simplex 2
-------------------- --------------------
# of avg. days # of avg. days
patients of lesions patients of lesions
---------- ------------ ---------- ------------
Group 1 controls
Men 7 9 6 10
Women 4 7 6 8
(total patients=23. Average lesion duration per patient=8.5 days)
Group 2 clinically treated
Men 13 3 4 12
Women 15 4 10 3
(total patients=42. Average lesion duration per patient=5.5 days)
Group 3 self treated
Men 5 0 4 0
Women 4 0 8 1
(total patients=21. Average lesion duration per patient=.25 day)
----------------------------------------------------------------
As can be seen the most successful group were those
who treated themselves prior to lesion onset, group #3.
The average duration of lesion existence for this
group was only 1/4 day. It was also discovered that the sooner treatment starts
after symptoms, the better the results. To prevent lesion formation it's
necessary to start treatment within the first 12 hours after onset of
symptoms.
Group 2 averaged 5 1/2 days lesion duration, and Group 1 averaged 8
1/2 days.
The data presented demonstrates that low voltage electrical
current, when applied to the lesion site, can significantly reduce the time of
persistence of that herpes lesion.
The data also shows more dramatically that
self treatment with low voltage electrical current within the first 15 minutes
of the occurrence of a symptom can prevent the occurrence of a lesion at that
site of stimulation.
HOME